Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has decided to open a new special account for the management and use of raised funds due to changes in certain fundraising projects, ensuring compliance with relevant regulations and protecting shareholder interests [1][2]. Group 1 - The meeting of the 8th Supervisory Board was held on May 17, 2025, with three supervisors present, chaired by Mr. Tan Zhenyou [1]. - The Supervisory Board approved the proposal to open a special account for raised funds, aimed at standardizing the management, storage, and use of these funds [1]. - The decision was made after careful review and voting, with all three supervisors in favor, and no objections or abstentions [2]. Group 2 - The opening of the special account aligns with the regulatory requirements outlined in the "Guidelines for the Management and Use of Raised Funds by Listed Companies" and other relevant laws [1]. - The Supervisory Board confirmed that the new account does not harm the interests of shareholders, particularly minority shareholders [1].

上海克来机电自动化工程股份有限公司 募集资金使用管理制度 二○二五年五月修订 上海克来机电自动化工程股份有限公司 募集资金使用管理制度 上海克来机电自动化工程股份有限公司 募集资金使用管理制度 第一章 总则 第一条 为进一步规范上海克来机电自动化工程股份有限公司（以下简称"公 司"）募集资金的管理和使用，提高募集资金使用的效率，防范资金风险，确保资 金安全，切实保护投资者利益，根据《中华人民共和国公司法》 《中华人民共和国证 券法》《上市公司募集资金监管规则》《上海证券交易所股票上市规则》（以下简称 "《上市规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等有关法律、法规和规范性文件规定和《上海克来机电自动化工程股份有限公司章 程》（以下简称"《公司章程》"）的规定，结合公司实际情况，特制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性质的 证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计划募集 的资金。 第三条 募集资金的使用应遵循集中管理、周密计划、预算控制、规范运作、公 开透明的原则。 第四条 公司募集资金应当按照招股说明书或者其他公 ...

第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金监管，但不包括公司实施股权激 励计划募集的资金监管。 第三条 募集资金到位后，按有关规定，公司应及时办理验资手续，由具有 证券从业资格的会计师事务所出具验资报告。 第四条 募集资金的使用应当符合招股说明书或者其他公开发行募集文件所 列用途使用。 第五条 公司的董事和高级管理人员应当勤勉尽责，督促公司规范使用募集 资金，确保公司募集资金安全，不得操控公司擅自或变相改变募集资金用途。 第六条 公司控股股东、实际控制人及其他关联人不得直接或者间接占用或 者挪用公司募集资金，不得利用公司募集资金及募集资金投资项目(以下简称 "募投项目")获取不正当利益。 募集资金管理办法 上海耀皮玻璃集团股份有限公司 募集资金管理办法 （尚需提交公司2024年年度股东大会审议通过后生效） 第一条 为规范上海耀皮玻璃集团股份有限公司（以下简称"公司"）募集 资金的管理和使用，切实保护投资者的利益，提高募集资金的使用效率，根据 《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司募集资 金监管规则》、《上海证券交易所上市 ...

Group 1 - The company has completed the cancellation of its special account for raised funds, with a zero balance as of the announcement date [3] - The total amount raised through the non-public offering was RMB 832 million, with a net amount of RMB 821.67 million after deducting issuance costs [1] - The company has permanently supplemented its working capital with surplus funds from completed investment projects, totaling RMB 81.81 million and RMB 136.73 million from different projects [2][3] Group 2 - The company signed a tripartite supervision agreement with its sponsor and bank to manage the raised funds [2] - The investment project "Annual Production of 40,000 Tons of High-Performance Composite Short Fiber Production Line" has reached its intended usable state, leading to its completion [2] - The company has terminated the investment project "Annual Production of 80,000 Tons of Composite Short Fiber Production Line Upgrade Project" due to changes in market conditions [2]

上海凤凰企业（集团）股份有限公司 第六条 公司应当在募集资金到账后一个月内与保荐机构、存放募集资金的商业 银行（以下简称商业银行）签订募集资金专户存储三方监管协议。该协议至少应当包 括以下内容： （一）公司应当将募集资金集中存放于募集资金专户； 第三条 本制度适用于募集资金的存储、使用、变更、监督和责任追究。 第四条 公司的董事和高级管理人员应当勤勉尽责，督促公司规范使用募集资金， 自觉维护公司募集资金安全。 第二章 募集资金的存储 第五条 公司募集资金应当存放于经董事会批准设立的专项账户（以下简称募集 资金专户）集中管理。 募集资金专户不得存放非募集资金或用作其它用途。 募集资金管理制度 第一章 总 则 第一条 为规范上海凤凰企业（集团）股份有限公司（以下简称公司）募集资金 的管理与使用，保护投资者合法权益，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司证券发行管理办法》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第1号——规范运作》《上市公司监管指引第2 号—上市公司募集资金管理和使用的监管要求》《上海凤凰企业（集团）股份有限公 司章程》（以下简称公司章程）等法律 ...

Core Points - The document outlines the management and usage of raised funds by Beijing Beilu Pharmaceutical Co., Ltd, emphasizing compliance with relevant laws and regulations [2][3][4] - The company is required to ensure that the use of raised funds aligns with the commitments made in the prospectus and cannot change the intended use without shareholder approval [3][4][6] - The document specifies the establishment of special accounts for raised funds, which must be managed separately from other funds [4][5][6] Fund Management - The company must conduct verification of raised funds by a qualified accounting firm and disclose the status of these funds in annual reports [4][6][7] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank where the funds are stored [6][7][8] - The company is required to ensure that raised funds are used for main business activities and cannot be used for high-risk investments or financial investments [9][10][11] Fund Usage - The company must follow the investment plan as stated in the issuance application and disclose any significant deviations from the plan [9][10][11] - Any changes in the use of raised funds must be approved by the board of directors and independent directors, and disclosed to shareholders [12][13][14] - The company must report on the progress of investment projects every six months and provide a special report on the use of raised funds [18][19][20] Fund Supervision - The internal audit department must check the status of raised funds at least quarterly and report findings to the board [36][37] - Independent directors can hire accounting firms to verify the use of raised funds if discrepancies are found [20][21] - Any violations in the use of raised funds that result in losses to the company will hold responsible personnel accountable [21][22]

General Principles - The purpose of the fundraising management system is to standardize the management of funds raised by the company, improve the efficiency and effectiveness of fund usage, and protect the interests of investors [1][2] - The funds raised refer to the money obtained by the company through the issuance of stocks and their derivatives for specific purposes [1] Fund Storage - The company must prudently select commercial banks and open special accounts for the raised funds, which should not be stored in the group's financial company [2][3] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank within one month of the funds being received [3][4] Fund Usage - The usage of raised funds must strictly follow the approval and decision-making procedures outlined in the system and relevant regulations [4][5] - The company must ensure that the use of funds aligns with the commitments made in the issuance application documents and must not change the direction of fund usage arbitrarily [5][6] Project Feasibility - The board of directors must fully verify the feasibility of fundraising projects, ensuring they have good market prospects and profitability [6][7] - Funds raised should primarily be used for the main business, and certain behaviors, such as financial investments or providing funds to controlling shareholders, are prohibited [7][8] Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board of directors and disclosed in a timely manner [8][9] - If a project is completed, any surplus funds must be used for other fundraising projects with board approval [10][11] Continuous Supervision - The finance department must maintain a ledger of the usage of raised funds, and the audit department must check the storage and usage at least every six months [12][13] - The board of directors must continuously monitor the actual management and usage of raised funds and disclose the situation accurately [14][15]

Fundraising Overview - The company has raised a total of RMB 2,529,664,782.94 through a non-public offering of 23,694,480 shares, approved by the China Securities Regulatory Commission [1] - The funds will be primarily used for the manufacturing project of high-end flip chip IC substrates, with a total investment of RMB 276,627,000 and planned fundraising of RMB 255,000,000 [1] Change of Project Implementation Entity - The company has approved a change in the project implementation entity for the high-end flip chip IC substrate manufacturing project from its wholly-owned subsidiary Wuxi Shennan to another wholly-owned subsidiary, Wuxi Guangxin Packaging Substrate Co., Ltd. [2] Fund Management and Storage - The company has revised its fundraising management system to ensure dedicated storage and usage of the raised funds, in compliance with relevant laws and regulations [2] - The management system includes provisions for fund storage, usage, project management, and supervision of investment projects [2] Fund Supervision Agreements - The company has signed tripartite and quadripartite supervision agreements with banks and underwriters to ensure proper management of the raised funds [3] - A new quadripartite supervision agreement was signed following the change of the project implementation entity [3] Fund Account Status - The company has closed several fundraising accounts, including those at China Bank and Agricultural Bank, as part of its fund management strategy [5] - The company has transferred RMB 54,764,800 from one of its fundraising accounts to its own funds and completed the account closure [6]

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. plans to use up to 100 million yuan of idle raised funds to temporarily supplement working capital, ensuring that it does not affect the construction of fundraising projects and the normal use of raised funds [1][4][5] Summary by Sections Fundraising Basic Information - The company has issued 60.01 million shares at a price of 16.24 yuan per share, raising a total of approximately 974.56 million yuan, with a net amount of 879.45 million yuan after deducting issuance costs [1][2] Fundraising Investment Project Overview - The total investment amount for the fundraising projects is 605.68 million yuan, with the entire amount allocated from the raised funds [2] - The company has decided to change part of the fundraising purpose, allocating 45 million yuan for the "Marketing Network Construction Project" and for acquiring 60% of the shares of Zhoushan Likang Pharmaceutical Chain Co., Ltd. [2] Previous Use of Idle Funds - The company previously used 150 million yuan of idle funds to supplement working capital, which has been fully returned to the fundraising account by May 8, 2025 [4] Current Use of Idle Funds - The company plans to use up to 100 million yuan of idle funds for working capital, with a usage period not exceeding 12 months from the board's approval date [4][5] - The use of these funds is limited to operations related to the main business and cannot be used for stock trading or other financial instruments [5] Necessity and Reasonableness - The decision to use idle funds is aimed at improving fund efficiency, reducing financial costs, and supporting the company's operational needs, thereby enhancing its competitive position in the pharmaceutical health sector [5][6] Review Procedures and Opinions - The board of directors, supervisory board, and independent directors have all approved the use of idle funds, confirming that the process complies with relevant regulations and does not affect the implementation of fundraising projects [6][7]

二、监事会会议审议情况 本次会议审议并通过如下议案： 经审议，监事会认为：董事会审议本次变更募集资金用途的程序符合《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等中国证监 会和深圳证券交易所规范性文件及公司《公司章程》《募集资金管理制度》等的 相关规定，公司本次变更部分募集资金用途事项，符合公司当前实际和发展需要， 有利于提高募集资金使用效率和长远利益，符合公司及全体股东的利益，不存在 损害公司、投资者特别是中小投资者利益的情形。 本议案尚需提交股东大会审议。 证券代码：301408 证券简称：华人健康 公告编号：2025-041 安徽华人健康医药股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 安徽华人健康医药股份有限公司（以下简称"公司"）第五届监事会第八次 会议已于 2025 年 5 月 16 日以书面、邮件送达形式发出通知，并于 2025 年 5 月 合相关法律法规及《公司章程》的规定，做出的决议合法有效。 经审议，监事会认为：本次使用闲置募集资金临时补充流动资金的审议程序 符合《上市公司监 ...